This Article Abstract Full Text (PDF) All Versions of this Article: 42/4/555    most recent 01.HYP.0000091265.94045.C7v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gauthier, K. M. Articles by Campbell, W. B. Search for Related Content PubMed PubMed Citation Articles by Gauthier, K. M. Articles by Campbell, W. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Coronary circulation Lipid and lipoprotein metabolism Endothelium/vascular type/nitric oxide

(Hypertension. 2003;42:555.)
© 2003 American Heart Association, Inc.

Scientific Contributions

14,15-Epoxyeicosa-5(Z)-Enoic-mSI

A 14,15- and 5,6-EET Antagonist in Bovine Coronary Arteries

From the Department of Pharmacology and Toxicology, Medical College of Wisconsin (K.M.G., W.B.C.), Milwaukee, and the Department of Biochemistry, University of Texas Southwestern Medical School (S.G.J., J.R.F.), Dallas.

Correspondence to William B. Campbell, PhD, Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226. E-mail wbcamp{at}mcw.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Endothelium-dependent hyperpolarizations and relaxation of vascular smooth muscle induced by acetylcholine and bradykinin are mediated by endothelium-derived hyperpolarizing factors (EDHFs). In bovine coronary arteries, arachidonic acid metabolites, epoxyeicosatrienoic acids (EETs), function as EDHFs. The 14,15-EET analog 14,15-epoxyeicosa-5(Z)-enoic-methylsulfonylimide (14,15-EEZE-mSI) was synthesized and tested for agonist and antagonist activity. In U46619-preconstricted bovine coronary arterial rings, 14,15-, 11,12-, 8,9-, and 5,6-EET induced maximal concentration-related relaxation averaging 75% to 87% at 10 µmol/L, whereas, 14,15-EEZE-mSI induced maximal relaxation averaging only 7%. 14,15-EEZE-mSI (10 µmol/L) preincubation inhibited relaxation to 14,15- and 5,6- EET but not 11,12- or 8,9- EET. 14,15-EEZE-mSI also inhibited indomethacin-resistant relaxation to arachidonic acid and indomethacin-resistant and L-nitroarginine-resistant relaxation to bradykinin and methacholine. It did not alter the relaxation to sodium nitroprusside, iloprost, or the K⁺ channel openers bimakalim or NS1619. In cell-attached patches of isolated bovine coronary arterial smooth muscle cells, 14,15-EEZE-mSI (100 nmol/L) blocked the 14,15-EET–induced (100 nmol/L) activation of large-conductance, calcium-activated K⁺ channels. Mass spectrometric analysis of rat renal cortical microsomes incubated with arachidonic acid showed that 14,15-EEZE-mSI (10 µmol/L) increased EET concentrations while decreasing the concentrations of the corresponding dihydroxyeicosatrienoic acids. Therefore, 14,15-EEZE-mSI inhibits relaxation to 5,6- and 14,15- EET and the K⁺ channel activation by 14,15-EET. It also inhibits the EDHF component of bradykinin-induced, methacholine-induced, and arachidonic acid–induced relaxation. These results suggest that 14,15- or 5,6 -EET act as an EDHF in bovine coronary arteries.

Key Words: vasodilation • arachidonic acids • endothelium-derived factors • acetylcholine • bradykinin

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Epoxyeicosatrienoic acids (EETs) are cytochrome P450 metabolites of arachidonic acid. The vascular endothelium synthesizes and releases EETs in response to vasoactive agonists such as bradykinin and acetylcholine.^1–5 In the coronary circulation, EETs activate smooth muscle membrane large-conductance, calcium-activated K⁺ (BK_Ca) channels to cause hyperpolarization and vascular relaxation.² Therefore, they function as endothelium-derived hyperpolarizing factors (EDHFs). Besides EETs, hydrogen peroxide, K⁺, and endocannabinoids are potential EDHFs.^6–8 The specific chemical mediator of EDHF activity varies, depending on vascular size, vascular bed, and species.⁹ Additionally, in small resistance arteries, electronic spread from the endothelium to the smooth muscle through gap junctions may mediate this activity.¹⁰

The functional characterization of EDHF activity has depended on the use pharmacological inhibitors. To investigate the role of EETs in EDHF-dependent relaxation, inhibitors of cytochrome P450 enzymes are used. In some studies, inhibitors of cytochrome P450 blocked the relaxation to bradykinin and acetylcholine, whereas in other studies, these inhibitors were without effect.^{1,2,4,5,11–15} In this regard, cytochrome P450 inhibitors may have other nonspecific vascular effects. For example, relaxation to potassium channel activators such as cromakalim or pinacidil was inhibited by some cytochrome P450 inhibitors.^13–15 Additionally, the P450 inhibitor clotrimazole directly inhibits Ca²⁺-activated K⁺ channels.^16–18 Therefore, to establish the role of endogenous EETs in vascular relaxation, pharmacological tools are required that selectively inhibit only the action or synthesis of EETs without other nonspecific effects.

Chemical modification of the EET molecule alters EET vascular activity. For 14,15-EET, shortening the distance between the carboxyl and epoxy groups, converting the epoxide oxygen to a sulfur or nitrogen, and changing the carboxyl group at carbon-1 to an alcohol or elimination of the 8 double bond results in loss of agonist potency.¹⁹ Furthermore, the 14,15-EET analogue 14,15-epoxyeicosaenoic acid [14,15-EE-5(Z)-E], with saturated double bonds between carbons 5,6 and 11,12, acts as an EET-specific antagonist. This analogue inhibits relaxation induced by 5,6-, 8,9-, 11,12-, 14,15-EET, and 14,15-DHET and inhibits the EDHF component of bradykinin- and acetylcholine-induced relaxation.²⁰ Because these alterations resulted in antagonist activity, further modifications may increase the potency of the antagonist activity or enhance regioisomer-specific properties. Therefore, we synthesized 14,15-epoxyeicosa-5(Z)-enoic-methylsulfonylimide (14,15-EEZE-mSI). 14,15-EEZE-mSI differs from 14,15-EEZE in that the carbon-1 carboxyl has been substituted with a methylsulfonimide group. Sulfonimide groups are commonly used as a substitute for carboxyl groups because they have a similar pKa.²¹ The sulfonimide group could enhance biological availability by blocking metabolism by ß-oxidation and by preventing esterification into membrane lipids.^22–24 This study evaluated agonist and antagonist properties of 14,15-EEZE-mSI and has characterized this molecule as a regioisomer-specific EET antagonist.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Vascular Reactivity Studies
Fresh bovine hearts were purchased from a local slaughterhouse. Sections of the left anterior descending coronary artery were dissected, cleaned, and cut into 1.5 to 2.0 mm diameter rings (3 mm length). The arterial rings were suspended in a tissue bath containing a Krebs-bicarbonate buffer equilibrated with 95% O₂–5% CO₂ and maintained at 37°C as previously described.^2,19,20 Tension was measured with a model FT-03C force transducer (Grass Instruments), ETH-400 bridge amplifier, and MacLab 8e A/D converter with MacLab software and a Macintosh computer. The arterial rings were slowly stretched to a basal tension of 3.5 g and equilibrated for 1.5 hours. KCl (40 to 60 mmol/L) was repeatedly added and rinsed until reproducible stable contractions were observed. The thromboxane mimetic U46619 (20 nmol/L) was added to increase basal tension to 50% to 75% of maximal KCl contraction. Relaxation responses to cumulative additions of the EETs, 14,15-DHET, sodium nitroprusside, bimakalim, NS1619, and iloprost were recorded, and the vessels were rinsed, treated with 14,15-EEZE-mSI, and the concentration-response to the agonist was repeated. In studies with arachidonic acid used as an agonist, the rings were pretreated with indomethacin (10 µmol/L) and in some instances with the epoxygenase inhibitor N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide, (MSPPOH, 10 µmol/L). For bradykinin and methacholine, the rings were pretreated with indomethacin (10 µmol/L) and L-nitroarginine (30 µmol/L). Basal tension represents tension before the addition of U46619. Results are expressed as percent relaxation of the U46619-treated rings, with 100% relaxation representing basal tension.

Metabolism of Arachidonic Acid
Rat renal cortical microsomes were prepared as previously described.^20,25 Microsomal protein (9 mg) was incubated in assay buffer of the following composition: (in mmol/L) KH₂PO₄ 80, K₂HPO₄ 20, MgCl₂ 10, and EDTA 1.0 with arachidonic acid (10 µmol/L), NADPH (1 mmol/L), and an NADPH-regenerating system containing isocitrate (10 mmol/L) and isocitrate dehydrogenase (0.1 U/mL) (total volume 2 mL) for 15 minutes at 37°C. Incubations were performed with vehicle or 14,15-EEZE-mSI (10 µmol/L). After the incubation, the samples were subjected to solid-phase extraction with the use of C₁₈ Bond Elut columns.^20,25 The samples were dried under a stream of nitrogen and analyzed by liquid chromatography–electrospray ionization–mass spectrometry (LC/ESI-MS, Agilent 1100 LC/MSD, SL model), as previously described.²⁵

Patch-Clamp Studies
Bovine coronary smooth muscle cells were enzymatically dissociated, and cell-attached, single-channel K⁺ currents were recorded by patch-clamp procedures as previously described.^2,26,27 Currents were sampled at 3 kHz and filtered at 1 kHz at a membrane potential of +20 mV. Perfusate and pipette solutions contained (in mmol/L) KCl 145, MgCl₂ 1.0, EGTA 1.0, HEPES 10, and 100 nmol/L ionized Ca²⁺ (pH 7.4). To determine the effects of 14,15-EET on the activity of the K⁺ channels, channel recordings (5 to 6 minutes) were obtained in cells perfused and incubated with either vehicle or 14,15-EEZE-mSI (100 nmol/L). Subsequently, 14,15-EET (100 nmol/L) was added, and after 3 minutes of incubation, K⁺ channel activity was again recorded.

Statistical Analysis
Vascular reactivity, patch-clamp, and mass spectrometry data are expressed as mean±SEM. Significance of differences between mean values was evaluated by Student t test or ANOVA, followed by the Student-Newman-Keuls multiple comparison test. Significance was accepted at a value of P<0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Structure of 14,15-EEZe-mSI
14,15-EEZE-mSI was synthesized by methods previously described.¹⁹ Figure 1 compares the chemical structures of 14,15-EET and 14,15-EEZE-mSI. 14,15-EEZE-mSI differs from 14,15-EET in that the double bonds at carbons 8,9 and 11,12 are saturated and the carbon-1 carboxyl was altered to a methylsulfonimide group.

View larger version (20K): [in this window] [in a new window]   Figure 1. Structures of 14,15-EET and 14,15-EEZE-mSI.

Effect of 14,15-EEZE on Agonist-Induced Relaxation of Coronary Arterial Rings
In U46619 precontracted arteries, 14,15-, 11,12 to 8,9-, and 5,6- EET caused concentration-related relaxation, as previously described.^2,20 In this study maximal relaxation to the EETs averaged 75% to 87% (Figure 2, A through D). 14,15-EEZE-mSI pretreatment caused a concentration-dependent inhibition of the 14,15-EET–induced relaxation. 14,15-EET maximal relaxation of 76±2% decreased to 67±6% and 33±5% after pretreatment with 1 µmol/L and 10 µmol/L 14,15-EEZE-mSI, respectively. 14,15-EEZE-mSI (10 µmol/L) pretreatment did not alter relaxation to 11,12- or 8,9-EET. However, 14,15-EEZE-mSI inhibited relaxation to 5,6-EET. 5,6-EET maximal relaxation of 75±3% decreased to 46±3% with pretreatment of this analogue. Relaxation to 14,15-DHET was also inhibited by 14,15-EEZE-mSI (Figure 2E). 14,15-DHET maximal relaxation of 88±3% decreased to 41±8% with 14,15-EEZE-mSI pretreatment. In contrast, 14,15-EEZE-mSI had little agonist activity. It maximally relaxed the precontracted arteries by 7±2% at 10 µmol/L (Figure 2F). Basal tension of the coronary arterial rings was not altered by 14,15-EEZE-mSI (1 nmol/L to 10 µmol/L, data not shown).

View larger version (24K): [in this window] [in a new window]   Figure 2. Effect of 14,15-EEZE-mSI on EET-induced (A through D) and 14,15-DHET–induced (E) relaxation of bovine coronary arteries and 14,15-EEZE-mSI–induced relaxation (F). Arterial segments were pretreated with U46619 (20 nmol/L). Arteries were preincubated with 1 µmol/L or 10 µmol/L 14,15-EEZE-mSI for (A) and 10 µmol/L 14,15-EEZE-mSI for (B through E). Changes in isometric tension were measured. *Significantly different from control, P0.05. All values are mean±SEM (n=7 to 20).

Next we evaluated the ability of this analogue to alter relaxation to other dilators. Sodium nitroprusside, an NO donor, iloprost, a prostacyclin analog, bimakalim, an ATP-sensitive K⁺ channel opener, and NS1619, a large-conductance, Ca²⁺-activated K⁺ channel (BK_Ca) opener, relaxed the coronary arteries (Figure 3). 14,15-EEZE-mSI (10 µmol/L) did not alter the concentration-dependent relaxation to iloprost or sodium nitroprusside (Figures 3A and 3B). Additionally, 14,15-EEZE-mSI did not alter the relaxation to the K⁺ channel activators bimakalim and NS1619 (Figures 3C and 3D). Therefore, 14,15-EEZE-mSI appears to specifically inhibit 14,15-induced and 5,6-EET–induced relaxation.

View larger version (24K): [in this window] [in a new window]   Figure 3. Effect of 14,15-EEZE-mSI (10 µmol/L) on iloprost-induced (A), sodium nitroprusside (SNP)-induced (B), bimakalim-induced (C), and NS1619-induced (D) relaxation of bovine coronary arteries. Arterial segments were pretreated with U46619 (20 nmol/L). Changes in isometric tension were measured. No significant effects were observed. All values are mean±SEM (n=4 to 7).

Additionally, contraction of arteries to increasing K⁺ concentrations (10 mmol/L to 80 mmol/L) was similar in arterial rings pretreated with either vehicle or 14,15-EEZE-mSI, with 14,15-EEZE-mSI causing a slight shift to the left of the concentration-response curve (EC₅₀=36.3±1.2 mmol/L, control versus 31.8±1.2 mmol/L, 14,15-EEZE-mSI, 10 µmol/L). Preincubation with 14,15-EEZE-mSI shifted the concentration-response curve of U46619 (10 pmol/L to 24 nmol/L) to the to the right, with EC₅₀s averaging 4.6±0.6 nmol/L and 13.2±1.1 nmol/L for control and 14,15-EEZE-mSI, respectively. This shift further indicates the slight agonist activity of this analog.

The ability of 14,15-EEZE-mSI to inhibit endothelium-dependent relaxation to bradykinin, methacholine, and arachidonic acid was evaluated (Figure 4). In the presence of indomethacin and L-NA, bradykinin-induced relaxation was shifted to the right 1000-fold by 14,15-EEZE-mSI (10 µmol/L) and maximal relaxation was reduced from 98±2% to 55±10% (Figure 4A). Similarly, indomethacin and L-NA–resistant relaxation to methacholine was reduced by 14,15-EEZE-mSI from a maximum of 75±4% to 48±8% (Figure 4B). The indomethacin-resistant relaxation to arachidonic acid was also reduced from a maximum of 87±7% to 54±4% by this inhibitor (Figure 4C). The supplementary addition of MSPPOH further decreased the arachidonic acid–induced maximal relaxation to 21±7%. Importantly, these data show that 14,15-EEZE-mSI inhibits the EDHF component of methacholine- and bradykinin-induced relaxation. This suggests that EETs, specifically 14,15- or 5,6-EET, contribute to the non-NO and nonprostaglandin relaxation to these agonists in bovine coronary arteries.

View larger version (16K): [in this window] [in a new window]   Figure 4. Effect of 14,15-EEZEm-SI (10 µmol/L) on bradykinin-induced (A), methacholine-induced (B), or arachidonic acid–induced (C) relaxation of bovine coronary arteries. Arterial segments were pretreated with U46619 (20 nmol/L). For bradykinin and methacholine, segments were pretreated with indomethacin (10 µmol/L) and L-nitroarginine (30 µmol/L); for arachidonic acid, segments were pretreated with indomethacin (10 µmol/L) or indomethacin plus MSPPOH (10 µmol/L). Changes in isometric tension were measured. *Significantly different from control, P0.05. All values are mean±SEM (n=6 to 16).

Effect of 14,15-EEZE-mSI on 14,15-EET-Induced Activation of BK_Ca Channels
In cell-attached patches of isolated bovine coronary arterial smooth muscle cells, we have previously demonstrated that 14,15-EET activates BK_Ca channels.^2,26 Consequently, we investigated the ability of 14,15-EEZE-mSI to block this activation. Recordings of BK_Ca channel activity in cell-attached patches are shown in Figure 5A. In the cell incubated with the vehicle, 14,15-EET (100 nmol/L) activated BK_Ca channel activity. In contrast, in the cell that was incubated with 14,15-EEZE-mSI (100 nmol/L), 14,15-EET failed to increase BK_Ca channel activity. Figure 5B summarizes the effect of 14,15-EEZE-mSI on channel mean open time (NP_o). 14,15-EET produced a 4-fold activation of channel NP_o. Incubation with 14,15-EEZE-mSI did not alter basal K⁺ channel activity but blocked the 14,15-EET-induced activation. Channel unitary conductance was similar in cells incubated with either vehicle or 14,5-EEZE-mSI and averaged 236±10 pS. Thus, 14,15-EEZE-mSI inhibits the 14,15-EET–induced activation of coronary smooth muscle BK_Ca channels.

View larger version (20K): [in this window] [in a new window]   Figure 5. Effect of 14,15-EEZE-mSI (100 nmol/L) on 14,15-EET–induced (100 nmol/L) activation of BKCa channels in cell-attached patches of isolated coronary smooth muscle cells. A, Single channel recordings of 14,15-EET activation of a cell incubated with vehicle control or a cell incubated with 14,15-EEZE-mSI. B, Summarized data of effect of 14,15-EEZE-mSI on 14,15-EET–induced activation of BKCa currents. n=5, 6 cells. *Significantly different from control, P0.05. All values are mean±SEM.

Effect of 14,15-EEZE-mSI on Arachidonic Acid Metabolism
To determine if 14,15-EEZE-mSI alters the synthesis of EETs, we investigated the effect of this analogue on arachidonic acid metabolism of rat renal cortical microsomes. Renal microsomes were chosen for this study because they produce large quantities of the four EET regioisomers and their metabolites, the DHETs. Microsomes converted arachidonic acid to 14,15-, 11,12-, 8,9-, 5,6-EET, and 20-HETE (Table). Larger amounts of DHETs were also formed. The presence of 14,15-EEZE-mSI (10 µmol/L) decreased concentrations of the DHET regioisomers while increasing the concentrations of the EETs. It did not alter 20-HETE concentrations. Therefore, 14,15-EEZE-mSI does not interfere with the synthesis of EETs or 20-HETE but appears to decrease the metabolism of EETs to DHETs by epoxide hydrolase.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
EETs function as EDHFs in the coronary, renal, and cerebral circulation.^{2,3,5,28–32} In bovine coronary arteries, EETs diffuse to the smooth muscle and activate membrane BK_Ca channels.^2,26 The four EET regioisomers are equipotent in relaxing preconstricted bovine coronary arterial rings, with maximal relaxation averaging 80%.^2,20 Therefore, in this vasculature, the specific position of the epoxide group does not appear critical for EET-induced relaxation. 14,15-DHET also induces relaxation of bovine coronary arterial rings, although relaxation is 5-fold less potent that the EETs.^19,27 Similar to 14,15-EET, 14,15-DHET activates coronary smooth muscle cell BK_Ca channels through G-protein–dependent mechanisms.²⁷ Thus, 14,15-EET and 14,15-DHET appear to induce smooth muscle hyperpolarization and relaxation through similar cellular mechanisms.

Previously, we characterized 14,15-EEZE as an EET-specific antagonist. This analogue blocked relaxation to all four EET regioisomers and 14,15-DHET but was most effective in inhibiting 14,15-EET. It also blocked the EDHF component of methacholine and bradykinin-induced relaxation.²⁰ 14,15-EEZE-mSI differs from 14,15-EEZE in that the carbon-1 carboxyl is replaced with a methylsulfonimide group. A similar substitution of carbon 1 of 14,15-EET with a methylsulfonimide group (14,15-EET-mSI) did not alter agonist properties.¹⁹ Additionally, 14,15-EET-mSI is not metabolized by smooth muscle cells or incorporated into cellular lipids.²⁴ Similarly, by using LC/ESI–mass spectrometric analysis of 14,15-EEZE-mSI metabolism in bovine coronary smooth muscle cells, we did not see evidence of ß-oxidation (data not shown). This substitution, therefore, could increase bioavailability by preventing membrane esterification and metabolism. However, it was not clear if this same substitution would alter agonist or antagonist properties of 14,15-EEZE. 14,15-EEZE-mSI showed little agonist activity. Conversely, preincubation with 14,15-EEZE-mSI blocked relaxation to 5,6-EET, 14,15-EET and 14,15-DHET. It did not alter relaxation to 8,9- and 11,12-EET. Therefore, this analogue appears to inhibit activity of eicosanoid agonists with an epoxide or hydroxyl group in either the 5,6 or 14,15 position. The reason for this specificity is not clear. 14,15-EEZE-mSI did not alter the ability of the bovine coronary arterial rings to relax to the NO-donor, sodium nitroprusside, the prostacyclin analog iloprost, or the K⁺ channel activators bimakalim or NS1619. Thus, 14,15-EEZE-mSI is not a nonselective inhibitor of vascular relaxation.

14,15-EEZE-mSI also inhibited the L-NA–resistant and indomethacin-resistant relaxation to bradykinin and methacholine and the indomethacin-resistant relaxation to arachidonic acid. Because this analogue only inhibited relaxation to 14,15- and 5,6-EET, this suggests that the EET regioisomer responsible for this EDHF activity is either 5,6- or 14,15-EET. Indeed, the EET regioisomer produced in the highest concentration by bovine coronary artery endothelial cells when stimulated by bradykinin or methacholine is 14,15-EET.³³ Therefore, these results provide additional evidence that 14,15-EET is the principle EET regioisomer responsible for EDHF activity in bovine coronary arteries.

14,15-EEZE-mSI did not completely block arachidonic acid–induced relaxation and was less effective than 14,15-EEZE.²⁰ The 14,15-EEZE-mSI–resistant relaxation to arachidonic acid was nearly eliminated by the epoxygenase inhibitor MSPPOH. Arachidonic acid is metabolized by the bovine coronary endothelium to all four EET regioisomers.²⁵ 14,15-EEZE-mSI, unlike 14,15-EEZE, only inhibits relaxation to 14,15- and 5,6-EET.²⁰ Thus, under these conditions, 14,15-EEZE-mSI could only inhibit the component of arachidonic acid–induced relaxation that was mediated by 14,15- and 5,6-EET. The remaining relaxation was inhibited by MSPPOH, an epoxygenase inhibitor that blocks the synthesis of all 4 EET regioisomers.

It is possible that 14,15-EEZE-mSI antagonism of EDHF activity occurs through the inhibition of EET synthesis rather than the blockade of EET activity. However, 14,15-EEZE-mSI increased the EET concentrations while decreasing DHET concentrations in the assays evaluating arachidonic acid metabolism. EETs are hydrolyzed to DHETs by epoxide hydrolases.³⁴ Similarly, 14,15-EEZE-mSI may be a substrate for epoxide hydrolases and compete with EETs for the epoxide hydrolase binding site. This competition would reduce the conversion of EETs to DHETs. However, this decreased conversion of EETs to DHETs would not explain the decreased EDHF-dependent relaxation induced by 14,15-EEZE-mSI.

In addition, we evaluated the ability of 14,15-EEZE-mSI to inhibit EET-induced activation of smooth muscle BK_Ca channels. In cell-attached patches, 14,15-EET activated BK_Ca channel open time by 4-fold. Incubation with 14,15-EEZE-mSI did not alter basal BK_Ca activity but blocked the 14,15-EET–induced activation. These results suggest that 14,15-EEZE-mSI antagonism of EDHF activity occurs through the blockade of EET action at the smooth muscle and not through the inhibition of EET synthesis in the endothelial cell or through the nonspecific inhibition of BK_Ca channels.

It is unclear if EET-induced vascular relaxation involves receptor-mediated mechanisms, even though EETs may stimulate BK_Ca channel activity through G-protein–dependent mechanisms.²⁶ In this regard, EETs may act at multiple regioisomer-specific binding sites. This is supported by the evidence that 14,15-EEZE-mSI inhibited 14,15-induced and 5,6-EET–induced relaxation but not relaxation induced by 8,9- or 11,12-EET. Furthermore, arteries from different vascular beds vary in the EET regioisomers that cause relaxation. For example, 11,12-EET but not 14,15-EET relaxed the rat renal artery,³⁵ only 5,6-EET induced relaxation in the rat tail artery,³⁶ and 14,15-EET and 11,12-EET induced relaxation whereas 8,9- and 5,6-EET did not in porcine coronary arterial rings.³⁷ Interestingly, 14,15-EEZE-mSI blocked 14,15-EET as well as 14,15-DHET–induced relaxation. The reasons for this interaction are not clear. However, this alludes to the possibility that 14,15-EET and 14,15-DHET act through the same receptor or binding site. Together, these results implicate a role for regioisomer, receptor-dependent mechanisms in EET-induced vascular activity and alteration of the EET molecule modifies these interactions.

Perspectives
The physiological importance of EDHF activity is becoming increasingly apparent as a major regulator of vascular tone. In the coronary circulation, the EETs function as EDHFs.^{1–3,28–31} EETs are cytochrome P450 metabolites of arachidonic acid, and investigations of the role of endogenous EETs have used cytochrome P450 inhibitors. However, these inhibitors may have nonspecific vascular effects and also block other vascular cytochrome P450 enzymes. Therefore, specific inhibitors of EET synthesis or action are required to fully characterize their activity. The results from this study have shown that the 14,15-EET analogue 14,15-EEZE-mSI acts as a regioisomer-specific antagonist of EET activity. 14,15-EEZE-mSI and other EET analogue antagonists will provide useful tools for the future evaluation of the role of endogenous EETs. Most importantly, impaired EHDF function may contribute to decreased dilator activity in vascular pathologies such as diabetes or hypertension.^9,38,39 These analogues will be useful for understanding the role of EETs in these conditions.

	Acknowledgments

 
This research was supported by grants from the National Institutes of Health (HL-51055 and GM-31278) and the Robert A. Welch Foundation. K. Gauthier was a postdoctoral fellow of the American Heart Association–Northland Affiliate and was supported by a National Institutes of Health Training Grant (HL-07792). The authors thank Sarah Hittner, Erik Edwards, Marilyn Isbell, and Christine Deeter for technical assistance and Gretchen Barg for secretarial assistance. They thank Kasem Nithipatikom for his advice with the LC/MS analysis.

Received April 22, 2003; first decision May 27, 2003; accepted August 5, 2003.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Pinto A, Abraham NG, Mullane KM. Arachidonic acid-induced endothelial-dependent relaxation of canine coronary arteries: contribution of a cytochrome P-450-dependent pathway. J Pharmacol Exp Ther. 1987; 240: 856–863.[Abstract/Free Full Text]

2. Campbell WB, Gebremehdin D, Pratt FP, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived relaxing factors. Circ Res. 1996; 78: 415–423.[Abstract/Free Full Text]

3. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 1999; 401: 493–497.[CrossRef][Medline] [Order article via Infotrieve]

4. Hecker M, Bara AT, Bauersachs J, Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol. 1994; 481: 407–414.[Abstract/Free Full Text]

5. Fulton D, McGiff JC, Quilley J. Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol. 1992; 107: 722–725.[Medline] [Order article via Infotrieve]

6. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000; 106: 1521–1530.[Medline] [Order article via Infotrieve]

7. Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K⁺ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998; 396: 269–272.[CrossRef][Medline] [Order article via Infotrieve]

8. Randall MD, Alexander SPH, Bennett T, Boyd EA, Fry JR, Gardiner SM, Kemp PA, McCulloch AI, Kendall DA. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Comm. 1996; 229: 114–120.[CrossRef][Medline] [Order article via Infotrieve]

9. Campbell WB, Gauthier KM. What is new in endothelium-derived hyperpolarizing factors? Curr Opin Nephrol. 2001; 11: 177–183.

10. Sandow SL, Hill CE. Incidence of myoendothelial gap junctions in the proximal and distal mesenteric arteries of the rat is suggestive of a role in endothelium-derived hyperpolarizing factor-mediated responses. Circ Res. 2000; 86: 341–346.[Abstract/Free Full Text]

11. Gauthier-Rein KM, Rusch NJ. Distinct endothelial impairment in coronary microvessels from hypertensive Dahl rats. Hypertension. 1998; 31: 328–334.[Abstract/Free Full Text]

12. Corriu C, Feletou M, Canet E, Vanhoutte PM. Inhibitors of the cytochrome P450-mono-oxygenase and endothelium-dependent hyperpolarizations in the guinea-pig isolated carotid artery. Br J Pharmacol. 1996; 117: 607–610.[Medline] [Order article via Infotrieve]

13. Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabatake A. Evidence against a role of cytochrome P450-derived arachidonic acid metabolites in endothelium-dependent hyperpolarization by acetylcholine in rat isolated mesenteric artery. Br J Pharmacol. 1997; 120: 439–446.[CrossRef][Medline] [Order article via Infotrieve]

14. Vanheel B, Van de Voorde J. Evidence against the involvement of cytochrome P450 metabolites in endothelium-dependent hyperpolarization of the rat main mesenteric artery. J Physiol. 1997; 501: 331–341.[Abstract/Free Full Text]

15. Van de Voorde J, Vanheel B. Influence of cytochrome P-450 inhibitors on endothelium-dependent nitro-L-arginine-resistant relaxation and cromakalim-induced relaxation in rat mesenteric arteries. J Cardiovasc Pharmacol. 1997; 29: 827–832.[CrossRef][Medline] [Order article via Infotrieve]

16. Devor DC, Singh AK, Gerlach AC, Frizzell RA, Bridges RJ. Inhibition of intestinal Cl^- secretion by clortrimazole: direct effect on basolateral membrane K⁺ channels. Am J Physiol. 1997; 273: C531–C540.[Medline] [Order article via Infotrieve]

17. Rittenhouse AR, Vandorpe DH, Brugnara C, Alper SL. The antifungal imidazole clotrimazole and its major in vivo metabolite are potent blockers of the calcium-activated potassium channel in murine erythroleukemia cells. J Membr Biol. 1997; 157: 177–191.[CrossRef][Medline] [Order article via Infotrieve]

18. Rittenhouse AR, Parker C, Brugnara C, Morgan KG, Alper SL. Inhibition of maxi-K currents in ferret portal vein smooth muscle cells by the antifungal clotrimazole. Am J Physiol. 1997; 273: C45–C56.[Medline] [Order article via Infotrieve]

19. Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Deeter C, Gauthier KM, Campbell WB. Comparison of the vasodilatory properties of 14, 15-EET analogs: structural requirements for dilation. Am J Physiol. 2002; 284: H337–H349.

20. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, Campbell WB. 14, 15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res. 2002; 90: 1028–1036.[Abstract/Free Full Text]

21. Backes BJ, Ellman JA. Carbon-carbon bond-forming methods on solid support: utilization of Kenner’s "safety-catch" linker. J Am Chem Soc. 1994; 116: 11171–11172.[CrossRef]

22. Fang X, Weintraub NL, VanRollins M, Spector AA. Functional implications of a newly characterized pathway of 11, 12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res. 1996; 79: 784–793.[Abstract/Free Full Text]

23. Fang X, VanRollins M, Kaduce TL, Spector AA. Epoxyeicosatrienoic acid metabolism in arterial smooth muscle cells. Circ Res. 1996; 79: 784–793.[Abstract/Free Full Text]

24. Snyder GD, Krishna UM, Falck JR, Spector AA. Evidence for a membrane site of action for 14,15-EET on expression of aromatase in vascular smooth muscle. Am J Physiol. 2002; 283: H1936–H1942.

25. Nithipatikom K, Grall AJ, Holmes BB, Harder DR, Falck JR, Campbell WB. Liquid chromatographic–electrospray ionization–mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal Biochem. 2001; 298: 327–336.[CrossRef][Medline] [Order article via Infotrieve]

26. Li P-L, Campbell WB. Epoxyeicosatrienoic acids activate K⁺ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res. 1997; 80: 877–884.[Abstract/Free Full Text]

27. Campbell WB, Deeter C, Ingraham RH, Falck JR, Li P-L. 14,15-Dihydroxyeicosatrienoic acid relaxes bovine coronary arteries by activation of K_Ca channels. Am J Physiol. 2002; 282: H1656–H1664.

28. Popp R, Bauersachs J, Hecker M, Fleming I, Busse R. A transferable, B-napthoflavone-inducible, hyperpolarizing factor is synthesized by native and cultured porcine coronary endothelial cells. J Physiol. 1996; 497: 699–709.[Abstract/Free Full Text]

29. Gebremedhin D, Harder DR, Pratt PF, Campbell WB. Bioassay of an endothelium-derived hyperpolarizing factor from bovine coronary arteries: role of a cytochrome P450 metabolite. J Vasc Res. 1998; 35: 274–284.[CrossRef][Medline] [Order article via Infotrieve]

30. Hayabachi Y, Nakaya Y, Matsuoka S, Kuroda Y. Endothelium-derived hyperpolarizing factor activates Ca²⁺-activated K⁺ channels in porcine coronary artery smooth muscle cells. J Cardiovasc Pharmacol. 1998; 32: 642–649.[CrossRef][Medline] [Order article via Infotrieve]

31. Fulton D, Mahboubi K, McGiff JC, Quilley J. Cytochrome P450-dependent effects of bradykinin in the rat heart. Br J Pharmacol. 1995; 114: 99–102.[Medline] [Order article via Infotrieve]

32. Gebremedhin D, Ma Y-H, Falck JR, Roman RJ, VanRollins M, Harder DR. Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial muscle. Am J Physiol. 1992; 263: H519–H525.[Medline] [Order article via Infotrieve]

33. Nithipatikom K, Pratt FR, Campbell WB. Determination of EETs using microbore liquid chromatography with fluorescence detection. Am J Physiol. 2000; 279: H857–H862.

34. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA. Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am J Physiol. 1999; 277: H2098–H2108.[Medline] [Order article via Infotrieve]

35. Zou AP, Fleming JT, Falck JR, Jacobs ER, Gebremedhin D, Harder DR, Roman RJ. Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K⁺-channel activity. Am J Physiol. 1996; 270: F822–F832.[Medline] [Order article via Infotrieve]

36. Carroll MA, Schwartzman M, Capdevila J, Falck JR, McGiff JC. Vasoactivity of arachidonic acid epoxides. Eur J Pharmacol. 1987; 138: 281–283.[CrossRef][Medline] [Order article via Infotrieve]

37. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res. 1997; 81: 258–267.[Abstract/Free Full Text]

38. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000; 130: 963–974.[CrossRef][Medline] [Order article via Infotrieve]

39. Shimokawa H. Endothelial function in hypertension. J Atheroscler Thomb. 1998; 4: 118–127.

This article has been cited by other articles:

				G. J. Gross, K. M. Gauthier, J. Moore, W. B. Campbell, J. R. Falck, and K. Nithipatikom Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H47 - H52. [Abstract] [Full Text] [PDF]

				Y. Ren, M. A. D'Ambrosio, J. L. Garvin, H. Wang, and O. A. Carretero Possible Mediators of Connecting Tubule Glomerular Feedback Hypertension, February 1, 2009; 53(2): 319 - 323. [Abstract] [Full Text] [PDF]

				W. Zhang, T. Otsuka, N. Sugo, A. Ardeshiri, Y. K. Alhadid, J. J. Iliff, A. E. DeBarber, D. R. Koop, and N. J. Alkayed Soluble Epoxide Hydrolase Gene Deletion Is Protective Against Experimental Cerebral Ischemia Stroke, July 1, 2008; 39(7): 2073 - 2078. [Abstract] [Full Text] [PDF]

				G. J. Gross, K. M. Gauthier, J. Moore, J. R. Falck, B. D. Hammock, W. B. Campbell, and K. Nithipatikom Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2838 - H2844. [Abstract] [Full Text] [PDF]

				W. Yang, B. B. Holmes, V. R. Gopal, R. V. K. Kishore, B. Sangras, X.-Y. Yi, J. R. Falck, and W. B. Campbell Characterization of 14,15-Epoxyeicosatrienoyl-Sulfonamides as 14,15-Epoxyeicosatrienoic Acid Agonists: Use for Studies of Metabolism and Ligand Binding J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1023 - 1031. [Abstract] [Full Text] [PDF]

				X.-Y. Yi, K. M. Gauthier, L. Cui, K. Nithipatikom, J. R. Falck, and W. B. Campbell Metabolism of adrenic acid to vasodilatory 1{alpha},1beta-dihomo-epoxyeicosatrienoic acids by bovine coronary arteries Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2265 - H2274. [Abstract] [Full Text] [PDF]

				W. B. Campbell and J. R. Falck Arachidonic Acid Metabolites as Endothelium-Derived Hyperpolarizing Factors Hypertension, March 1, 2007; 49(3): 590 - 596. [Abstract] [Full Text] [PDF]

				T. Lu, D. Ye, X. Wang, J. M. Seubert, J. P. Graves, J. A. Bradbury, D. C. Zeldin, and H.-C. Lee Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms J. Physiol., September 1, 2006; 575(2): 627 - 644. [Abstract] [Full Text] [PDF]

				D. Ye, W. Zhou, T. Lu, S. G. Jagadeesh, J. R. Falck, and H.-C. Lee Mechanism of rat mesenteric arterial KATP channel activation by 14,15-epoxyeicosatrienoic acid Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1326 - H1336. [Abstract] [Full Text] [PDF]

				K. M. Gauthier, E. M. Edwards, J. R. Falck, D. S. Reddy, and W. B. Campbell 14,15-Epoxyeicosatrienoic Acid Represents a Transferable Endothelium-Dependent Relaxing Factor in Bovine Coronary Arteries Hypertension, April 1, 2005; 45(4): 666 - 671. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 42/4/555    most recent 01.HYP.0000091265.94045.C7v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gauthier, K. M. Articles by Campbell, W. B. Search for Related Content PubMed PubMed Citation Articles by Gauthier, K. M. Articles by Campbell, W. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Coronary circulation Lipid and lipoprotein metabolism Endothelium/vascular type/nitric oxide